share_log

Stephens & Co. Initiates Coverage On Cytek Biosciences With Overweight Rating, Announces Price Target of $9

Stephens & Co. Initiates Coverage On Cytek Biosciences With Overweight Rating, Announces Price Target of $9

Stephens & Co.以增持评级启动对Cytek Biosciences的报道,宣布目标股价为9美元
Benzinga ·  2023/12/14 05:46

Stephens & Co. analyst Mason Carrico initiates coverage on Cytek Biosciences (NASDAQ:CTKB) with a Overweight rating and announces Price Target of $9.

斯蒂芬斯公司分析师梅森·卡里科以增持评级启动了对Cytek Biosciences(纳斯达克股票代码:CTKB)的报道,并宣布目标股价为9美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发